AI Article Synopsis
- - The study focuses on a trial for treating advanced maxillary sinus cancer by using high-dose cisplatin via a specific method while also applying radiotherapy.
- - During the dose-finding phase, researchers aimed to identify any serious side effects and establish how many treatment cycles of cisplatin patients should receive.
- - Out of 18 patients, most completed 7 treatment cycles, and the therapy was found to be safe and tolerable, establishing 7 cycles as the recommended approach for these cancer patients.
Article Abstract
Background: We are currently undertaking a multi-institutional prospective trial of the superselective intra-arterial infusion of high-dose cisplatin with concomitant radiotherapy for patients with T4aN0M0 or T4bN0M0 locally advanced maxillary sinus squamous cell carcinomas (SCC). We herein report the results of the dose-finding phase.
Methods: The dose-finding phase sought to evaluate the incidence of dose-limiting toxicities and determine the recommended number of cycles of the intra-arterial infusion of cisplatin. In this phase, 100 mg/m of cisplatin was administered intra-arterially weekly for 7 weeks with concomitant radiotherapy (70 Gy).
Results: All 18 patients received a full dose of radiotherapy. The number of cycles of cisplatin was 7 in 13 patients and 6 in 5 patients. The dose-limiting toxicities were observed in 5 patients.
Conclusion: These results indicated that this therapy is safe and well-tolerated at 7 cycles of cisplatin, which was determined to be the recommended number of cycles for locally advanced maxillary sinus SCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/hed.25001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phospholipid Nanoparticles: A Novel Colloid for Blood Volume Replacement, Reanimation, and Organ Protection in Hemorrhagic Shock.
Biomedicines
December 2024
Department of Surgery, School of Medicine, University of Missouri Kansas City, Kansas City, MO 64108, USA.
: Exsanguination is a leading cause of preventable death in military and civilian settings due to extensive blood loss and hemorrhagic shock, which trigger systemic effects such as impaired tissue perfusion, hypoxia, inflammation, and multi-organ dysfunction. Standard resuscitation restores blood volume but fails to address critical aspects of hemorrhagic shock, including inflammation, coagulopathy, and reperfusion injury. To address these limitations, novel phospholipid nanoparticle (PNP)-based resuscitative fluids, VBI-S and VBI-1, were developed to modulate nitric oxide (NO) levels, improving hemodynamic stability, tissue oxygenation, and reducing inflammatory injury.
View Article and Find Full Text PDFDosing optimisation of intravenous lidocaine in patients with class 1-3 obesity by population pharmacokinetic analysis.
Anaesthesia
January 2025
Department of Anaesthesia and Perioperative Medicine, The Royal Brisbane and Women's Hospital, Brisbane, Australia.
Article Synopsis
- The study focused on developing an optimized lidocaine dosing regimen for obese patients during surgery, highlighting the need for more effective pain management.
- Researchers gathered data from 30 patients, measuring plasma levels of lidocaine and its metabolites to create a pharmacokinetic model.
- The findings suggested that current dosing was often inadequate, but an adjusted regimen could improve the likelihood of reaching therapeutic drug concentrations.
Continuous intra-arterial infusion chemotherapy using a port-catheter for nasopharyngeal carcinoma.
J Vasc Interv Radiol
December 2024
Department of Interventional Radiology, Hospital Israelita Albert Einstein, Sao Paulo, (SP), Brazil.
Successful treatment of tumor lysis syndrome associated with hepatic artery infusion chemotherapy in a patient with hepatocellular carcinoma: a case report.
J Med Case Rep
December 2024
Liver Cancer Institute, National Clinical Research Center for Interventional Medicine, Zhongshan Hospital, Fudan University, 136 Yi Xue Yuan Road, Shanghai, 200032, People's Republic of China.
Background: Tumor lysis syndrome is a life-threatening complication in the treatment of cancer. However, it rarely occurs in solid tumors, especially in hepatocellular carcinoma.
Case Presentation: We present a 52-year-old male Asian patient with advanced hepatocellular carcinoma treated with hepatic artery infusion chemotherapy that resulted in tumor lysis syndrome.
Arterial Infusion and Isolated Perfusion in Combination with Reversible Electroporation for Locally Relapsed Unresectable Breast Cancer.
Cancers (Basel)
November 2024
Department Surgical Oncology, Medias Klinikum, 84489 Burghausen, Germany.
Background: Relapsed unresectable triple-negative breast cancer is a demanding disease with only a few treatment options. Especially for patients with unresectable tumor masses, a treatment that offers rapid tumor shrinkage is needed. If patients are exhausted from several treatment lines, systemic side effects have to be avoided.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!